Belay Diagnostics Summit™ Informed Clinical Decisions in 93% of Cases in Large Real-World CNS Study May 6, 2026
CSF Liquid Biopsy May Help Clarify Inconclusive Leptomeningeal Disease Cases, Study Finds April 14, 2026
Belay Diagnostics Reports 82% Clinical Impact Rate for Summit™ and Vantage™ in CNS Lymphoma Study March 24, 2026
Belay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF) January 19, 2026
Belay Diagnostics Announces the Validation of Vantage™ Assay for Evaluation of MGMT Promoter Methylation in Cerebrospinal Fluid (CSF) July 7, 2025
Belay Diagnostics Receives NIH Award to Advance Multi-Omic CSF Assay for Brain Cancer Diagnosis May 9, 2025
Belay Diagnostics Announces US Commercial Launch of Summit™: Breakthrough CSF Testing for CNS Cancer Detection and Management April 25, 2025
Belay Diagnostics Partners with GenomOncology to Support High-Performance Liquid Biopsy Test for Central Nervous System Cancer Detection March 25, 2025
